Effect of new nutraceutical formulation with policosanol, berberine, red yeast rice, cassia nomame, astaxantine and Q10 coenzyme in patients with low-moderate dyslipidemia associate with intolerance to statins and metabolic syndrome

Preliminary studies underline that berberine, monacolink, hydroxytyrosol and Q10 coenzyme can be used to control cholesterol level. The aim of our study was to evaluate the effect of a new nutraceutical formulation with policosanol, berberina, red yeast rise, cassia nomame, astaxantina, Q10 coenzime and folic acid in patients with low to moderate dyslipidemia, intolerance to statins and metabolic syndrome. Our observational study supports the claim that this drug formulation possess anti-cholesterol activity. The study also showed that, compared with berberine-monacolink-hydroxytyrosol-Q10 Co-enzyme, the new formulation with policosanol-berberine-red yeast rice-cassia nomame-astaxantine-Q10 coenzyme exhibits higher antidyslipidemic effects